A versatile plasmid system for reconstitution and analysis of mammalian ubiquitination cascades in yeast by Trezza, R.A. (Rossella Avagliano) et al.
  
 
 
OPEN ACCESS | www.microbialcell.com 150 Microbial Cell | MARCH 2018 | Vol. 5 No. 3 
www.microbialcell.com 
Research Article 
ABSTRACT  Ubiquitination is a posttranslational protein modification that 
regulates most aspects of cellular life. The sheer number of ubiquitination 
enzymes that are present in a mammalian cell, over 700 in total, has thus far 
hampered the analysis of distinct protein ubiquitination cascades in a cellular 
context. To overcome this complexity we have developed a versatile vector 
system that allows the reconstitution of specific ubiquitination cascades in 
the model eukaryote Saccharomyces cerevisae (baker’s yeast). The vector 
system consists of 32 modular yeast shuttle plasmids allowing inducible or 
constitutive expression of up to four proteins of interest in a single cell. To 
demonstrate the validity of the system, we show that co-expression in yeast 
of the mammalian HECT type E3 ubiquitin ligase E6AP (E6-Associated Protein) 
and a model substrate faithfully recapitulates E6AP-dependent substrate 
ubiquitination and degradation. In addition, we show that the endogenous 
sumoylation pathway of S. cerevisiae can specifically sumoylate mouse PML 
(Promyelocytic leukemia protein). In conclusion, the yeast vector system de-
scribed in this paper provides a versatile tool to study complex post-
translational modifications in a cellular setting. 
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INTRODUCTION 
The process of ubiquitination, involving the covalent con-
jugation of the small protein ubiquitin (Ub) to a substrate 
protein, is one of the most finely tuned mechanisms of 
post-translational modification in eukaryotic biology [1]. 
Ubiquitination is accomplished through an elaborate en-
zymatic cascade involving the concerted action of three 
distinct types of enzymes: E1 Ub-activating, E2 Ub-
conjugating and E3 Ub ligase. First, Ub is activated by one 
of two cellular E1 enzymes, then transferred to ~40 E2 en-
zymes that interact with more than 600 E3 ligases. The 
substrate specificity is determined in the last step of the 
cascade, catalysed by the E3, in which Ub is covalently at-
tached to a lysine residue of a specific target protein [2]. 
The two main groups of E3 ligases are HECT (Homologous 
to E6-AP C-terminus) and RING (Really interesting new 
gene) ligases. The HECT E3s contain a conserved active site 
cysteine that acts as an acceptor for Ub from E2 conjugat-
ing enzymes. The Ub is then transferred onto a Lysine resi-
due of the target protein. RING E3s ligases on the other 
hand do not have an active site cysteine, but function as a 
scaffold that enhances the transfer of Ub from the E2 ac-
tive site directly onto the substrate [3].  
Ub itself contains seven lysine residues and a N-
terminal NH2 group, each of which can serve as a substrate 
of ubiquitination, resulting in the formation of Ub chains 
consisting of multiple Ub moieties. This ability of Ub to 
form chains of at least eight different linkages adds to the 
complexity of the ubiquitination system. Indeed, the fate 
of the ubiquitinated substrate is, to a large extent, deter-
mined by the length and type of linkage between Ub moie-
ties [4]. For example, chains linked via Lys63 (K63) are im-
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plicated in DNA repair, signaling and endocytosis [5]. On 
the other hand, substrates that receive poly-ubiquitin 
chains linked via Lys48 (K48) or Lys11 (K11) are targeted for 
degradation by the 26S proteasome [6, 7], a multi-protein 
complex responsible for proteolysis and ubiquitin recycling. 
The 26S proteasome is a conserved proteolytic machinery 
present in both the nucleus and the cytosol of eukaryotic 
cells [8]. Proteasomes are also present in some bacterial 
species where they are involved in the degradation of 
pupylated proteins [9], a type of post-translational modifi-
cation that is functionally analogous to ubiquitination, but 
chemically distinct [10]. 
The analysis of specific ubiquitination cascades in a cel-
lular setting is a major challenge given that mammalian 
cells express more than 700 ubiquitination enzymes, which 
often have overlapping substrate specificities [11, 12]. To 
reduce complexity, cell-free approaches have been devel-
oped that utilize reconstituted ubiquitination cascades. 
However, these cell-free assays require extensive protein 
purification of the respective ubiquitination enzymes as 
well as their substrate. A bacterial ubiquitination system 
has recently been developed that allows the analysis of 
specific ubiquitination cascades in a cellular context [13]. 
The intrinsic differences of proteasomes in bacteria [9], 
however, limit the analysis of ubiquitinated substrates. To 
overcome these limitations we have established a cellular 
system for reconstitution of mammalian E3 ubiquitin lig-
ase-dependent substrate modification and degradation. 
This system employs the model eukaryote Saccharomyces 
cerevisiae (baker’s yeast) as a host for co-expression of E2, 
E3 and substrate of a specific mammalian ubiquitination 
cascade, while the yeast cell provides the ubiquitin and the 
E1 enzyme. Yeast shuttle plasmids were developed that 
allow expression and detection of up to four proteins of 
interest in a single yeast cell. Gene expression is regulated 
by three different types of promoters: galactose inducible 
GAL1 promoter (available in three different strengths), the 
CuSO4 inducible CUP promoter or the strong constitutive 
TEF promoter. To improve stability and detection of poly-
ubiquitinated targets, a strain was constructed that lacks 
the ABC transporter PDR5 rendering the cells more suscep-
tible to the proteasome inhibitor MG132 [14].  
Here we demonstrate the validity of our system by 
showing specific ubiquitination and proteasomal degrada-
tion of an established target of E6AP, a HECT type E3 ligase 
that is deficient in patients with Angelman syndrome [15, 
16]. In addition, we demonstrate that the system can also 
be used to study other types of post-translational modifi-
cations by showing sumoylation of the mouse PML protein 
in yeast. 
 
RESULTS AND DISCUSSION 
Plasmid construction 
To enable study of mammalian ubiquitination cascades in 
yeast we constructed a modular set of plasmids (called 
pRA) that allow for: a) inducible or constitutive expression 
of the enzymes of the ubiquitination cascade and sub-
strates, and b) detection of the gene products bearing N-
FIGURE 1: Schematic representation of the constructed vectors. The pRA vectors (A) are yeast centromeric shuttle plasmids that carry an 
auxotrophic marker (URA3, TRP1 or LEU2 gene) for selection in yeast and the ampicillin (Amp) resistance gene for selection in E. coli. The 
gene of interest can be cloned into the multiple cloning site (MCS) under control of either the inducible GAL1 promoter (3 different 
strengths) or the constitutive TEF promoter. The expressed protein will bear any of the four (Flag, Myc, HA or V5) N-terminal epitope tags 
allowing easy detection. All restriction sites indicated are unique. (B) High copy (2 μm) yeast shuttle plasmids carrying the HIS3 auxotrophic 
marker and expressing either 6xHis-Myc tagged ubiquitin (Ub) or SUMO (Smt3) under control of the copper inducible promoter (CUP). CTA1 
and Cyc1 term (inator), transcription termination sequences derived from the yeast Catalase A and Cytochrome c1 gene, respectively. 
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terminal epitope tags. The plasmid backbone for the vector 
system is derived from the YCplac series of single copy 
yeast shuttle plasmids that carry the URA3, TRP1 or LEU2 
auxotrophic selection markers [17]. To induce expression 
of the gene of interest we made use of the tightly con-
trolled GAL1 promoter [18]. The GAL1 promoter is actively 
repressed by glucose and changing the carbon source from 
glucose to galactose induces protein expression. The use of 
an inducible promoter can facilitate the expression of toxic 
proteins [19]. The GAL1 promoter exists in three different 
versions, “strong” (93% activity, contains four Gal4p Up-
stream Activating Sequences [UAS], “medium” (31% activi-
ty, three Gal4p UASs) and “weak” (15% activity, two Gal4p 
UASs), allowing further fine-tuning of gene expression lev-
els. In order to facilitate constitutive expression we em-
ployed the strong TEF promoter [20]. To enable protein 
detection four distinct N-terminal epitope tags, HA, V5, 
Flag and Myc were inserted in each plasmid. Finally, each 
plasmid harbours a new multiple cloning site (MCS) with 
unique restriction sites for facile cloning of the gene of 
interest. The pRA vector system currently consists of 32 
plasmids each of which harbours a different combination 
of promoter, tag and auxotrophic marker (see also Table 
S1), but this set can be extended up to 48 by including all 
available GAL1 promoter variants (Fig 1). The advantage of 
pRA vector system compared to previously published col-
lections of yeast expression vectors [21, 22, 23] is that dif-
ferent N-terminal epitope tags are included in the vector 
allowing simultaneous expression and detection of multi-
ple genes of interest in a single yeast cell. To facilitate the 
detection and purification of ubiquitinated (or sumoylated) 
substrates two separate high copy (2 μm) plasmids were 
constructed that express either 6xHis-Myc tagged ubiquitin 
or 6xHis-Myc tagged SUMO (Smt3) under the control of the 
copper inducible promoter CUP1 [24]. These two plasmids 
harbor the HIS3 auxotrophic marker and each can be com-
bined with up to three pRA plasmids, bringing the total 
number of genes expressed in a single yeast cell to four. 
 
Galactose inducible expression 
To test the functionality of the GAL1 promoter plasmids we 
cloned E6-E7, one of the canonical targets of the HECT E3 
ligase E6AP, in three different vectors harboring the 93%-, 
31%- and 15%-GAL1 promoter, respectively (see Material 
and methods). The E6-E7 fusion protein consists of the 
entire human papillomavirus (HPV)-16 E7 fused to HPV-16 
E6 [25]. E6-E7 was tagged at its N-terminus with the Flag 
tag. Constructs were transformed into yeast yRA2, a deriv-
ative of S. cerevisiae strain BY4741 in which the TRP1 gene 
was knocked out (see Material and methods). Trans-
formants were first cultured in medium containing 2% glu-
cose, then shifted to a medium with 2% raffinose and 0.1% 
glucose, and finally inoculated in medium containing 2% 
galactose to induce expression of E6-E7 for the indicated 
time points. As shown in Figure 2, E6-E7 was undetectable 
in total lysates of cells grown in 2% raffinose/0.1% glucose 
medium (t=0), indicating tight glucose repression of E6-E7 
expression. Within 30 min after the shift to galactose-
containing medium E6-E7 could be detected in cells ex-
pressing the gene from the strongest version of the GAL1 
promoter, the 93%-GAL1. All three promoter-versions 
showed a gradual increase of E6-E7 expression with time, 
reaching the highest levels with the 93%-GAL1 promoter. 
Taken together, these data show that by using different 
versions of the GAL1 promoter protein expressions levels 
can be modulated.  
 
E6AP-dependent ubiquitination of E6-E7 
Previous work has shown that the E6-E7 fusion protein is 
efficiently ubiquitinated by E6AP in a cell-free system [25]. 
We therefore set out to determine whether E6AP is capa-
ble of specifically ubiquitinating the E6-E7 fusion protein in 
the heterologous yeast system. To reconstitute this specific 
ubiquitination cascade in yeast, mouse E6AP (wild-type 
and the catalytically inactive mutant, E6AP-C817S) and its 
cognate E2, mouse UBCH7, were cloned under control of 
the constitutive TEF promoter, each bearing different tags 
(HA for E6AP and Flag for UBCH7). The yRA2 strain, in 
which the plasma-membrane ABC transporter Pdr5 was 
deleted by homologous recombination, was co-
transformed with E6-E7 (V5 tag, 93%-GAL1 promoter), 
E6AP (wt or mutant) and either UBCH7 or an empty plas-
mid. Transformants were pre-cultured on 2% raffi-
nose/0.1% glucose and shifted to 2% galactose to induce 
the expression of E6-E7. After 1 hour of galactose induction, 
75 µM MG132 was added to inhibit proteasomal activity 
FIGURE 2: Galactose inducible expression of E6-E7. Yeast strain yRA2 transformed with E6-E7 cloned in pRA1 (Flag tag, URA3 marker, 93%-
GAL1 promoter), pRA2 (Flag tag, URA3 marker, 31%-GAL1 promoter) and pRA3 (Flag tag, URA3 marker, 15%-GAL1 promoter), was induced for 
the indicated time points by the addition of 2% galactose. Cells were lysed and equivalent amounts of protein extract were analyzed by SDS-
PAGE and anti-Flag immunoblotting. Hexokinase is used as a loading control. 
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and allow accumulation of ubiquitinated proteins [26]. 
Immunoblot analysis of yeast total lysates revealed that, in 
addition to the band corresponding to the unmodified E6-
E7 fusion protein, slower migrating bands accumulated in 
cells expressing wild type E6AP (Figure 3A). The fact that 
these bands are absent in cells co-expressing the catalyti-
cally inactive E6AP (E6AP-C817S) suggests that E6-E7 can 
be ubiquitinated in yeast in an E6AP-dependent manner. 
To  unambiguously  show  that these slower  migrating spe- 
cies represent (poly)-ubiquitinated forms of E6-E7 the ex-
periment was repeated with cells co-transformed with 
6xHis-Myc-tagged ubiquitin (6xHis-Myc-Ub, driven by the 
CUP1 promoter) or empty plasmid. Efficient conjugation of 
6xHis-Myc-Ub to proteins was verified by anti-myc im-
munoblotting (Figure S1). Conjugation of the recombinant 
6xHis-Myc-Ub to a protein will result in a slower electro-
phoretic mobility of the ubiquitinated protein compared to 
a protein modified with wild-type (endogenous) ubiquitin 
due to the addition of the 6xHis-Myc tag on ubiquitin. As 
shown in Figure 3B (right panel) the slower migrating E6-E7 
bands observed in cells expressing the catalytically active 
E6AP shifted to an apparent higher molecular weight upon 
overexpression of 6xHis-Myc-Ub. This data confirm that 
these slower migrating bands are indeed the result of 
E6AP-dependent ubiquitination of E6-E7. Notably, in the 
absence of UBCH7, similar levels of E6-E7 ubiquitination 
were observed indicating that one of the endogenous 
yeast E2 enzymes [27] can functionally interact with E6AP 
to ubiquitinate its target (Figure S2). This data support the 
notion that for the analysis of a specific mammalian ubiqui-
tination cascade in yeast, expression of the E3 ligase and its 
target may be sufficent, a major advantage in cases where 
not all components of the specific ubiquitination cascade 
are known. 
 
Degradation of E6-E7 
To test if E6AP-dependent poly-ubiquitination of E6-E7 
leads to proteasome-mediated degradation of the fusion 
protein in the reconstituted yeast system, we performed a 
cycloheximide (CHX) chase experiment. Yeast cells were 
FIGURE 3: E6AP-dependent ubiquiti-
nation of E6-E7. (A) Yeast strain yRA2 
was transformed with E6AP (wild type 
or catalytically inactive mutant) cloned 
in pRA306 (HA tag, LEU2 marker, TEF 
promoter), UBCH7 cloned in pRA300 
(Flag tag, URA3 marker, TEF promoter) 
and E6-E7 cloned in pRA20 (V5 tag, 
TRP1 marker, 93%-GAL1 promoter). 
Following 1 hour of galactose induc-
tion, cells were treated with 75 μM 
MG132 for the indicated time points. 
Cells were lysed and equivalent 
amounts of protein extract were ana-
lyzed by SDS-PAGE and immunoblot-
ting using the indicated antibodies. (B) 
Yeast strain yRA2 was transformed 
with E6AP (wild type or catalytically 
inactive mutant) cloned in pRA306 (HA 
tag, LEU2 marker, TEF promoter), E6-
E7 cloned in pRA20 (V5 tag, TRP1 
marker, 93%-GAL1 promoter) and 
6xHis-Myc-Ub (Myc tag, HIS3 marker, 
CUP promoter) or empty p423 vector. 
Expression of 6xHis-Myc-Ub was in-
duced by addition of CuSO4 (100 μM). 
Following 1 hour of galactose induc-
tion, cells were treated with 50 μM 
MG132 for 120 min. Cells were lysed 
and equivalent amounts of protein 
extract were analyzed by SDS-PAGE 
and immunoblotting using anti-V5 
antibody. The band marked with an 
asterisk (*) is an example of an ubiqui-
tinated E6-E7 band that in cells over-
expressing 6xHis-Myc-Ub, generates 
additionally slower migrating species 
(arrow head) due to the incorporation 
of the 6xHis-Myc-tagged ubiquitin. 
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co-transformed with E6-E7, UBCH7, and E6AP-wt or E6AP-
C817S. After galactose induction, protein synthesis was 
inhibited by treating the cells with 50 μg/ml CHX for the 
indicated times (Figure 4). In cells expressing E6AP-wt, E6-
E7 rapidly disappeared upon addition of CHX. In contrast, 
no appreciable reduction of E6-E7 levels was observed in 
cells co-transformed with the catalytically inactive E6AP 
(E6AP-C817S). These data indicate that E6AP-catalyzed 
ubiquitination of E6-E7 in yeast results in rapid protein 
degradation, a process most likely mediated by the 26S 
proteasome. Together, we show that a complex cellular 
mechanism such as the ubiquitination and degradation of a 
substrate via the ubiquitin proteasome system can be re-
constituted in yeast by expressing only the specific E3 and 
its substrate. Such an approach is only possible in a model 
eukaryotic setting, such as yeast, where biological mecha-
nisms are highly conserved. 
 
Sumoylation of promyelocytic leukemia protein 
Another example of a biological process that is conserved 
between mammals and yeast is sumoylation, a post-
translational modification very similar to ubiquitination 
[28]. Sumoylation is the process by which proteins are co-
valently tagged with a SUMO (small ubiquitin- like modifi-
er) moiety that shares ~20% similarity with Ub. SUMO pro-
teins are highly conserved from yeast to mammals. In yeast, 
only one SUMO protein (Smt3) exists, while mammalian 
cells express three major SUMO isoforms (SUMO-1, SUMO-
2, and SUMO-3). Sumoylation, the linkage of SUMO to a 
target protein through an isopeptide bond, is catalyzed by 
a series of enzymatic reactions similar to that of ubiquitina-
tion. First, SUMO/Smt3 is activated by an E1 SUMO-
activating enzyme (SAE1/2 in mammals and UBA2 in yeast), 
which is followed by transfer of the activated SUMO/Smt3 
to a SUMO-specific E2, Ubc9. From here, either the SU-
MO/Smt3 is directly transferred to a lysine side-chain of 
the target protein or the transfer is indirectly and requires 
an SUMO E3 ligase. In contrast to ubiquitination, sumoy-
lation often occurs on a consensus motif, Ψ-K-x-D/E (Ψ; 
hydrophobic residue, K; lysine, x; any amino acid and D/E; 
aspartic acid/glutamic acid) [28]. The PML protein offers a 
well-established example of a protein that is sumoylated. 
PML is the key player in the generation of Nuclear Bodies 
(NB) involved in a myriad of processes, including cellular 
senescence, virus response, and apoptosis [29]. PML con-
tains three sumoylation consensus motifs each of which 
are targeted by sumoylation. Sumoylation of these consen-
sus lysines is essential for the recruitment of nuclear pro-
teins to the NB [30, 31].   
To test if PML sumoylation can be recapitulated in yeast 
we overexpressed V5-tagged mouse PML under the control 
of the 93%-GAL1 promoter in presence or absence of 
6xHis-Myc-Smt3 driven by the CUP1 promoter. As shown in 
Figure 5A, following galactose-induction and in the absence 
of 6xHis-Myc-Smt3 up to three slower migrating bands 
appeared above the main band representing PML, suggest-
ing targeting of all three consensus-sumoylation sites in 
PML. In cells overexpressing 6xHis-Myc-Smt3 these slower 
migrating bands were split up in two or more bands indi-
cating successful incorporation of recombinant 6xHis-Myc-
Smt3 and supporting the notion that these slower migrat-
ing species represent sumoylated forms of PML. Similar 
results were obtained when human PML was expressed in 
yeast (data not shown). This data strongly suggest that 
sumoylation of mouse PML can be faithfully reproduced in 
yeast by employing its endogenous sumoylation machinery. 
In line with previous observations [32] overexpression of 
PML resulted in an overall increase of Smt3-conjugated 
species, most likely representing Smt3 linked to PML and 
to endogenous yeast proteins (Fig. 5B). How PML stimu-
lates Smt3 conjugation in yeast remains to be determined.  
In conclusion, we show that the use of a model eukary-
ote, in combination with a highly versatile plasmid system 
that allows regulated expression of multiple heterologous 
proteins, can facilitate the analysis of complex (mammali-
an) post-translational modification cascades such as ubiq-
uitination and sumoylation in a cellular context. 
 
MATERIALS AND METHODS 
Plasmid generation 
The vector backbone of the pRA plasmids is pEL43 [33], an 
YCplac33 derived yeast shuttle plasmid [17] harboring the CTA 
(Catalase A) promoter and CTA terminator separated by a 
multiple cloning site (MCS), the URA3 auxotrophic marker and 
the ARS1/CEN4 region for autonomous replication in yeast. 
The three different GAL1 promoters (93%, 31% and 15%) were 
FIGURE 4: E6AP-dependent 
degradation of E6-E7. Yeast 
strain yRA2 was transformed 
with E6AP, UBCH7 and E6-E7 
as described in the legend to 
Figure 3. Following 1 hour of 
galactose induction, cells were 
treated with 50 μg/ml CHX for 
the indicated time points. 
Cells were lysed and equiva-
lent amounts of protein ex-
tract were analyzed by SDS-
PAGE and immunoblotting 
using the indicated antibodies. 
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obtained by PCR on yeast genomic DNA using primers contain-
ing a 5’ NarI and a 3’ SacI site, respectively (Table S2) and sub-
sequently cloned in pEL43 digested with NarI and SacI, there-
by replacing the CTA promoter with the GAL1 promoter se-
quences. Next, a new MCS was inserted in each of the three 
vectors between the PstI and HindIII sites using double 
stranded (ds) oligonucleotides (Table S2). At this point, ds 
oligonucleotides encoding the four different N-terminal 
epitope tags (HA, V5, Flag and Myc) followed by an AscI site 
were inserted between the SacI and BamHI restriction sites of 
each plasmid. Finally, the URA3 auxotrophic marker in these 
plasmids was replaced by TRP1 or LEU2 by cloning the NarI-
AatII fragments encompassing promoter, tag, MCS and CTA 
terminator into YCplac22 (TRP1) and Ycplac111 (LEU2) digest-
ed with NarI and AatII. The TEF promoter was obtained by PCR 
from pTEF-URA [34] (generous gift of Jens Nilsen) using pri-
mers containing a 5’ NarI and a 3’ SacI and subsequently 
cloned in pRA1, 4, 7, 10 and 13-20, digested with NarI and SacI, 
thereby replacing the 93%-GAL1 promoter with the TEF pro-
moter sequence. Ubch7 (Ube2l3) was amplified by PCR from 
image clone BC106149 (clone ID 4502101) using primers con-
taining a 5’ AscI and a 3’ SalI site, respectively (Table S2) and 
subsequently cloned in pRA300 digested with AscI and SalI. To 
obtain a higher expression of the E2 enzyme, the CEN/ARS1 
sequence in pRA58 was replaced by the 2 μm origin of replica-
tion derived from YEplac195, resulting in plasmid pRA60. 
Ube3a was amplified by PCR with primers p881 and p882 from 
mouse brain cDNA (generous gift of Ype Elgersma) and subse-
quently cloned in pRA306. Pml was amplified by PCR from 
image clone BC020990 (clone ID 4188386) using primers con-
taining a 5’ AscI and a 3’ SalI site, respectively (Table S2) and 
subsequently cloned in pRA20. E6-E7 fusion protein was am-
plified by fusion PCR (to delete the internal SalI site) from 
plasmid #95 [25] (generous gift of Jon Huibregtse) using exter-
nal primers containing a 5’ BamHI and a 3’ SalI site, respective-
ly (S2 Table) and subsequently cloned in pRA20, generating 
pJB322. The BamHI-NotI fragment encompassing E6-E7 was 
isolated from pJB322 and cloned in plasmids pRA1, pRA2 and 
pRA3 digested with BamHI andNotI. 
6xHis-Myc-Ub and 6xHis-Myc-Smt3 plasmids are based on 
p423, a multi-copy (2 μm) yeast shuttle plasmid harboring the 
MET25 promoter, Cyc1 terminator and HIS3 auxotrophic 
marker [23]. A three fragment ligation was used to construct 
6xHis-Myc-Ub as follows: the EcoRI-MluI fragment from 
pCW129 [35] encompassing 6xHis-Myc-Ub and part of the 
Cyc1 terminator sequences and the SacI-EcoRI fragment from 
pES7 (generous gift of Mike Ellison, University of Alberta) har-
boring the CUP1 promoter were ligated into p423 digested 
with SacI and MluI, generating 6xHis-Myc-Ub (pBD238, Table 
S2). To construct 6xHis-Myc-Smt3, the Smt3 gene was ampli-
fied from yeast genomic DNA, thereby introducing a 5’ BamHI 
site and a 3’ KpnI site. The BamHI-KpnI fragment was subse-
quently cloned into pCW129 digested with BglII and KpnI, 
thereby replacing the Ub gene with Smt3. The BamHI-MluI 
fragment of the resulting plasmid, encompassing the CUP 
promoter, 6xHis-Myc-Smt3 and part of the Cyc1 terminator 
sequences, was isolated and cloned into pBD238 cut with 
BamHI and MluI, generating 6xHis-Myc-Smt3 (pNO3, S1 Table). 
A complete list of plasmids generated in this study can be 
found in Table S1. Plasmids will be deposited at Addgene. 
 
Yeast strains 
Strain yRA1 was derived from S. cerevisiae strain BY4741 (MA-
Ta his3Δ1 leu2Δ0 met15Δ0 ura3Δ0) by partial deletion of the 
TRP1 gene (0.51 kb deletion) using the loxP/Cre gene disrup-
tion and marker rescue procedure as previously described [36]. 
This deletion keeps elements of the UAS (upstream activating 
sequence) required for expression of the adjacent GAL3 gene 
intact thereby not affecting the kinetics of galactose induction 
[37]. The loxP/Cre system was also used to delete the ABC 
transporter gene PDR5 in yRA1 thereby generating yRA2. 
 
 
FIGURE 5: Sumoylation of 
mouse PML in yeast. Yeast strain 
yRA1 was transformed with PML 
cloned in pRA20 (V5 tag, TRP1 
marker, 93%-GAL1 promoter) 
and with a plasmid expressing 
6xHis-Myc-Smt3 under control of 
the CUP promoter (HIS3 marker) 
or with empty vector. Expression 
of PML and Smt3 was induced by 
addition of galactose (2% [w/v]) 
and CuSO4 (100 μM), respective-
ly. Cells were lysed and equiva-
lent amounts of protein extract 
were analyzed by SDS-PAGE and 
anti-V5 (A) or anti-Myc (B) im-
munoblotting. The band marked 
with an asterisk (*) in panel A is 
an example of PML modified by a 
single Smt3 moiety that, in cells 
overexpressing 6xHis-myc-Smt3, 
gives rise to a slower migrating 
species (arrow head) due to 
covalent attachment of the 
6xhis-Myc-tagged Smt3. 
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Yeast transformation 
Transformation of S. cerevisiae cells was conducted as previ-
ously described using the lithium-acetate protocol [38]. 
 
Galactose induction 
On day 1, yeast colonies transformed with the desired plas-
mid(s) were inoculated in 3 ml of minimal medium (2% [w/v] 
glucose, 0.67% [w/v] Yeast Nitrogen Base [DIFCO] and amino 
acids as required) and incubated over night (O/N) at 28°C 
while shaking at 200 rpm.  
On day 2, cells of the O/N culture were re-inoculated in 10 
ml of minimal medium at an OD600 of 0.2 and grown until they 
reached an OD600 of 0.8 (approx. 7-8h). Upon reaching the 
desired OD value, cells were re-inoculated in 10 ml of raffinose 
minimal medium (2% [w/v] raffinose, 0.1% [w/v] glucose, 
0.67% [w/v] Yeast Nitrogen Base [DIFCO] and amino acids as 
required) at a starting OD600 of 0.05 and grown O/N  (16h) at 
28°C while shaking (200 rpm). 
On day 3, O/N cultures were re-inoculated at OD600 of 0.2 
in rich raffinose medium (2% [w/v] Bacto peptone, 1% [w/v] 
Bacto yeast extract, 2% [w/v] raffinose, 0.1% [w/v] glucose) 
and grown to an OD600 of 0.5 (approx. 3-4h). An uninduced 
sample was taken before adding 2% galactose [w/v] to the 
cultures in order to induce protein expression. At the desired 
time points, samples were taken and the absorbance meas-
ured at 600 nm. 
 
Ubiquitination assay 
For the ubiquitination assay, cultures were treated with 75 μM 
or 50 μM MG132 (SelleckBio) or an equivalent volume of 
DMSO after 1 hour of galactose induction. Samples were tak-
en at the indicated time points and total protein lysates were 
prepared. 
 
Degradation assay 
For the degradation assay, cultures were treated with 50 
μg/ml cycloheximide (CHX)(Sigma) after 1 hour of galactose 
induction. Samples were collected at the indicated time points 
in ice-cold sodium azide (10 mM final concentration) to pre-
vent undesired protein degradation. 
 
Protein extracts and immunoblotting  
Protein extracts were prepared by breaking the cells with glass 
beads and acid precipitation essentially as previously de-
scribed [39]. Aceton washed protein pellets were dried, re-
suspended in 1X Laemmli-sample buffer (0.2 M Tris-HCl [pH 
6.8], 1.5% sodium dodecyl sulfate [SDS], 10% glycerol, 1 mM 
EDTA, 0.004% bromophenol blue) containing 50mM DTT, 
heated for 10 min at 65°C and separated by SDS-PAGE. Protein 
transfer and detection was done essentially as previously de-
scribed [40]. The primary antibodies used included anti-HA rat 
monoclonal peroxidase-conjugated antibody (3F10; Roche), 
anti-Myc mouse monoclonal antibody (Cell Signaling CST2276), 
anti-myc-HRP (Thermo Fisher R951-25), anti-V5-HRP (Thermo 
Fisher R961-25), anti-Flag monoclonal antibody (M2 Sigma) 
and anti-Hexokinase polyclonal antibody. 
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